- In September 2024, AbbVie announced the expansion of its clinical trials for Upadacitinib (Rinvoq) to evaluate its efficacy in treating alopecia areata and ulcerative colitis. This move underscores the company's commitment to broadening the therapeutic applications of Rinvoq, a selective JAK1 inhibitor, to address unmet medical needs in autoimmune and inflammatory conditions. The trials aim to further validate its potential as a versatile treatment option in the growing JAK inhibitor market
- In October 2020, AbbVie revealed new data demonstrating the long-term efficacy and safety of Abrocitinib, its JAK1 inhibitor, for the treatment of atopic dermatitis. The findings highlighted sustained symptom relief and an acceptable safety profile, reinforcing the potential of Abrocitinib as a reliable therapeutic option for managing this chronic inflammatory skin condition. This development has further solidified AbbVie's position as a leader in innovative treatments for dermatological diseases
